Akari Therapeutics Plc EV/EBIT
Cos'è EV/EBIT di Akari Therapeutics Plc?
EV/EBIT di Akari Therapeutics Plc è N/A
Qual è la definizione di EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT di aziende nel Health Care settore su NASDAQ rispetto a Akari Therapeutics Plc
Cosa fa Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Aziende con ev/ebit simili a Akari Therapeutics Plc
- Canadian General Investments ha EV/EBIT di N/A
- Omnia Metals Ltd ha EV/EBIT di N/A
- Netgear Inc ha EV/EBIT di N/A
- Vroom ha EV/EBIT di N/A
- OncoSec Medical Inc ha EV/EBIT di N/A
- Hemogenyx Pharmaceuticals Plc ha EV/EBIT di N/A
- Akari Therapeutics Plc ha EV/EBIT di N/A
- Youngevity International Inc ha EV/EBIT di N/A
- Sigma Labs Inc ha EV/EBIT di N/A
- GOLO Mobile ha EV/EBIT di N/A
- NeuroOne Medical Technologies ha EV/EBIT di N/A
- Vision Marine Technologies ha EV/EBIT di N/A
- Medicenna Therapeutics ha EV/EBIT di N/A